A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study

被引:35
作者
Sharma, Kuldeep [1 ]
Giri, Kalpeshkumar [1 ]
Dhiman, Vinay [1 ]
Dixit, Abhishek [1 ]
Zainuddin, Mohd [1 ]
Mullangi, Ramesh [1 ]
机构
[1] Jubilant Biosys, Bangalore 560022, Karnataka, India
关键词
methotrexate; tofacitinib; LC-MS; MS; method validation; rat plasma; pharmacokinetics; ACTIVE RHEUMATOID-ARTHRITIS; CP-690,550; COMBINATION; INHIBITION; PATHWAY; DISEASE;
D O I
10.1002/bmc.3348
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A highly sensitive, specific and rapid LC-ESI-MS/MS method has been developed and validated for simultaneous quantification of methotrexate (MTX) and tofacitinib (TFB) in rat plasma (50 L) using phenacetin as an internal standard (IS), as per the US Food and Drug Administration guidelines. After a solid-phase extraction procedure, the separation of the analytes and IS was performed on a Chromolith RP18e column using an isocratic mobile phase of 5 m m ammonium acetate (pH 5.0) and acetonitrile at a ratio of 25:75 (v/v) using flow-gradient with a total run time of 3.5 min. The detection was performed in multiple reaction monitoring mode, using the transitions of m/z 455.2 308.3, m/z 313.2 149.2 and m/z 180.3 110.2 for MTX, TFB and IS, respectively. The calibration curves were linear over the range of 0.49-91.0 and 0.40-74.4 ng/mL for MTX and TFB, respectively. The intra- and interday accuracy and precision values for MTX and TFB were <15% at low quality control (QC), medium QC and high QC and <20% at lower limit of quantification. The validated assay was applied to derive the pharmacokinetic parameters for MTX and TFB post-dosing of MTX and TFB orally and intravenously to rats. Copyright (c) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:722 / 732
页数:11
相关论文
共 24 条
[1]  
[Anonymous], 2001, Guidance for Industry: Bioanalytical Method Validation
[2]  
Bonfiglio R, 1999, RAPID COMMUN MASS SP, V13, P1175, DOI 10.1002/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.3.CO
[3]  
2-S
[4]   Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial [J].
Burmester, Gerd R. ;
Blanco, Ricardo ;
Charles-Schoeman, Christina ;
Wollenhaupt, Juergen ;
Zerbini, Cristiano ;
Benda, Birgitta ;
Gruben, David ;
Wallenstein, Gene ;
Krishnaswami, Sriram ;
Zwillich, Samuel H. ;
Koncz, Tamas ;
Soma, Koshika ;
Bradley, John ;
Mebus, Charles .
LANCET, 2013, 381 (9865) :451-460
[5]   Mechanisms of disease: Cytokine pathways and joint inflammation in rheumatoid arthritis. [J].
Choy, EHS ;
Panayi, GS .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) :907-916
[6]   Current Understanding of Rheumatoid Arthritis Therapy [J].
Colmegna, Ines ;
Ohata, Brent R. ;
Menard, Henri A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (04) :607-620
[7]   Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis [J].
Dowty, Martin E. ;
Jesson, Michael I. ;
Ghosh, Sarbani ;
Lee, Jamie ;
Meyer, Debra M. ;
Krishnaswami, Sriram ;
Kishore, Nandini .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2014, 348 (01) :165-173
[8]  
EMA, 2009, EMEACHMPEWP192217200
[9]   Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis [J].
Fleischmann, Roy ;
Kremer, Joel ;
Cush, John ;
Schulze-Koops, Hendrik ;
Connell, Carol A. ;
Bradley, John D. ;
Gruben, David ;
Wallenstein, Gene V. ;
Zwillich, Samuel H. ;
Kanik, Keith S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (06) :495-507
[10]   Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) [J].
Ghoreschi, Kamran ;
Jesson, Michael I. ;
Li, Xiong ;
Lee, Jamie L. ;
Ghosh, Sarbani ;
Alsup, Jason W. ;
Warner, James D. ;
Tanaka, Masao ;
Steward-Tharp, Scott M. ;
Gadina, Massimo ;
Thomas, Craig J. ;
Minnerly, John C. ;
Storer, Chad E. ;
LaBranche, Timothy P. ;
Radi, Zaher A. ;
Dowty, Martin E. ;
Head, Richard D. ;
Meyer, Debra M. ;
Kishore, Nandini ;
O'Shea, John J. .
JOURNAL OF IMMUNOLOGY, 2011, 186 (07) :4234-4243